Floatz logo

Veltuzumab

Recurrent or Refractory B Cell Acute Lymphoblastic Leukaemia

Queen Mary University of Londonmonoclonal_antibodyPhase 1/2Dormant
CCC
48/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
33/ 100
Competitive Position
95/ 100

Competitive context

141 Active assets in the Recurrent or Refractory B Cell Acute Lymphoblastic Leukaemia cohort.

Asset / SponsorPhaseRating
ETOPOSIDE
University of Washington
Phase 3BBB
ASPARAGINASE ERWINIA CHRYSANTHEMI (RECOMBINANT)
City of Hope Medical Center
Phase 3BB
VINCRISTINE SULFATE
City of Hope Medical Center
Phase 3BB
Dasatinib
National Cancer Institute (NCI)
Phase 3BB
PEGASPARGASE
National Cancer Institute (NCI)
Phase 3BB

View all 50 →

Same molecule, other indications

Veltuzumab is also rated in:

non-Hodgkin lymphomaDormant
B
Indicative ·
58 / 100
View asset →
CLLDormant
CCC
Indicative ·
55 / 100
View asset →
PLASMACYTOMADormant
CCC
Indicative ·
52 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →